Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation

Rhea-AI Summary

Kadmon Holdings announced that its drug REZUROCK (belumosudil) has been added to the NCCN Guidelines for Graft-Versus-Host Disease (GVHD) management with a Category 2A designation. This follows FDA approval on July 16, 2021, for chronic GVHD treatment in patients aged 12 and older after failure of two prior therapies. The drug's inclusion in NCCN signals its potential clinical impact as a commendable therapy for steroid-refractory chronic GVHD, enhancing awareness among healthcare providers and patients.

Positive

• REZUROCK has received NCCN Guidelines inclusion with a Category 2A designation.
• FDA approval for REZUROCK supports its use for chronic GVHD after two prior therapies.
• Clinical studies indicate REZUROCK is well tolerated and effective for chronic GVHD.

Negative

• None.

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network^® (NCCN) added REZUROCK^TM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease (GVHD). The NCCN Guidelines in the United States now include REZUROCK with a Category 2A designation as a suggested systemic agent for steroid-refractory chronic GVHD.

"The rapid inclusion of REZUROCK into the NCCN guidelines shortly after full FDA approval validates the potential clinical impact of REZUROCK in this difficult-to-treat therapeutic landscape," said Harlan W. Waksal, MD, President and CEO of Kadmon. "We are grateful for this important development as we continue in our efforts to increase awareness of REZUROCK among the healthcare provider community and patients living with chronic GVHD."

On July 16, 20201, the U.S. Food and Drug Administration (FDA) approved REZUROCK (belumosudil) 200 mg once daily (QD) for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

The FDA approval of REZUROCK is based on safety and efficacy results from ROCKstar (KD025-213), a randomized, open-label, multicenter pivotal trial of REZUROCK in patients with cGVHD who had received two to five prior lines of systemic therapy. Based on the ROCKstar study, the NCCN guidelines suggest that "belumosudil is a promising therapy for steroid-refractory cGVHD that is well tolerated and produces clinically meaningful responses."

NCCN is a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient and accessible cancer care so patients can live better lives.

The updated NCCN Guidelines are available at www.nccn.org.

NCCN^® and the NCCN Guidelines^® are registered trademarks of National Comprehensive Cancer Network.

About cGVHD

cGVHD is a complication that can occur following allogeneic stem cell transplantation, resulting in significant morbidity and mortality. In cGVHD, transplanted immune cells (graft) attack the patient's cells (host), leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus and gastrointestinal tract. Approximately 14,000 patients in the United States are living with cGVHD.

About REZUROCK™ (belumosudil)

REZUROCK™ (belumosudil) is the first and only approved therapy targeting Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and fibrotic processes. REZUROCK is approved in the United States for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy. For more information, visit www.REZUROCK.com. The FDA granted Breakthrough Therapy designation and Priority Review for REZUROCK and reviewed the New Drug Application (NDA) under the Real-Time Oncology Review (RTOR) pilot program.

Kadmon is also developing belumosudil for the treatment of systemic sclerosis. The FDA has granted Orphan Drug Designation to belumosudil for the treatment of systemic sclerosis.

INDICATIONS AND USAGE

REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Embryo-Fetal Toxicity: Based on findings in animals and its mechanism of action, REZUROCK can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

The most common (≥20%) adverse reactions, including laboratory abnormalities, in patients receiving REZUROCK were infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension.

To report suspected adverse reactions, contact Kadmon at 1-877-377-7862 or the FDA at (800) FDA-1088 or www.fda.gov/medwatch.

Use in Specific Populations

Lactation: Advise not to breastfeed.

Please visit www.REZUROCK.com to see the full Prescribing Information for REZUROCK.

About Kadmon

Kadmon is a biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. REZUROCK™ (belumosudil), an oral, once-daily, tablet, is approved in the United States for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy. Kadmon's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. For more information, please visit www.kadmon.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, our expectations regarding REZUROCK™ (belumosudil) as a new available therapy, the timing of commercial availability of REZUROCK in the U.S., the commercial launch of REZUROCK in the U. S., the degree the NCCN Guidelines® influence the best course of treatment and supportive care for people living with cGVHD, and the potential benefit of our clinical and preclinical development programs for immune and fibrotic diseases as well as immuno-oncology therapies. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," "contemplate" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statement contained in this press release, including, without limitation, (i) our ability to commercialize REZUROCK and execute on our marketing plans for any other drugs or indications that may be approved in the future, (ii) risks that REZUROCK revenue, expenses and costs may not be as expected, (iii) risks relating to REZUROCK's market acceptance, competition, reimbursement and regulatory actions, (iv) risks and uncertainties related to the severity and duration of the impact of COVID-19 on our business and operations, including, without limitation, commercial and clinical drug supply chain continuity and the commercial launch of REZUROCK, (v) our ability to obtain and maintain reimbursement for REZUROCK and any approved product and the extent to which patient assistance programs and copay programs are utilized, (vi) our ability to successfully demonstrate the efficacy and safety of our product candidates including in later-stage studies, (vii) availability and timing of data from our preclinical and clinical trials, which may not support further development of our product candidates, (viii) our ability to manage our reliance on sole-source third parties such as our third party drug substance and drug product contract manufacturers, (ix) actions of regulatory agencies, (x) the inherent uncertainty in estimates of patient populations and incidence and prevalence estimates, (xi) competition from other products, (xii) our ability to comply with healthcare regulations and laws, (xiii) our ability to obtain, maintain and enforce our intellectual property rights, (xiv) our ability to maintain and establish strategic agreements and collaborations and the potential benefits of those arrangements and (xv) other risks, including active or potential litigation risks, any or all of which of the foregoing may affect the initiation, timing and progress of clinical studies and the timing of and our ability to obtain additional regulatory approvals, and make our investigational drugs and REZUROCK available to patients, and to derive revenue from product sales. More detailed information about us and the risk factors that may affect the realization of our forward-looking statements are set forth in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and subsequent filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, except as may be required by law. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Contact Information
833.900.5366
Investors@kadmon.com

SOURCE: Kadmon Holdings, Inc.

View source version on accesswire.com:
https://www.accesswire.com/658453/Kadmon-Announces-REZUROCKTM-belumosudil-Added-to-National-Comprehensive-Cancer-NetworkR-Clinical-Practice-Guidelines-in-Oncology-for-Hematopoietic-Cell-Transplantation

FAQ

What is the significance of REZUROCK's addition to the NCCN Guidelines?

REZUROCK's inclusion in the NCCN Guidelines indicates its recognition as a valuable treatment for steroid-refractory chronic GVHD.

When was REZUROCK approved by the FDA?

REZUROCK was approved by the FDA on July 16, 2021.

What condition does REZUROCK treat?

REZUROCK is indicated for chronic graft-versus-host disease (cGVHD) in patients 12 years and older who have not responded to at least two prior lines of systemic therapy.

What does a Category 2A designation from NCCN mean?

A Category 2A designation means that REZUROCK is suggested as a systemic agent for treatment based on clinical evidence.

What were the results of the ROCKstar trial for REZUROCK?

The ROCKstar trial demonstrated that REZUROCK is well tolerated and produces meaningful clinical responses in cGVHD patients.